GHRH-mediated GH release is associated with sympathoactivation and baroreflex resetting: a microneurographic study in healthy humans

What Was Tested

The paper reports a study of GHRH (Growth Hormone-Releasing Hormone), published as a controlled clinical trial.

This cross talk can be presumed both during physiological (e.g., slow-wave sleep) and pathological conditions of GH release.

However, microneurographic studies of muscle sympathetic nerve activity (MSNA) and assessment of baroreflex function during acute GH-releasing hormone (GHRH)-mediated GH release were not conducted so far.

Who Took Part

The abstract describes 11 volunteers taking part.

The age groups tagged for this paper are young adults and adults, men only.

How the Study Was Run

In design terms this was a double-blind, placebo-controlled and crossover study.

Neither the volunteers nor the staff measuring them knew who was on GHRH (Growth Hormone-Releasing Hormone), so expectations could not easily colour the readings.

Some volunteers received a placebo instead of GHRH (Growth Hormone-Releasing Hormone), giving a reference point.

In the crossover set-up each of the volunteers took both GHRH (Growth Hormone-Releasing Hormone) and the comparison in turn, acting as their own control.

MSNA was assessed microneurographically and correlated with blood pressure (BP) and heart rate (HR) at rest before (pre-) and 30-45 (post-I) and 105-120 min (post-II) after respective injections.

Additionally, baroreflex function was assessed via graded infusion of vasoactive drugs.

What Was Measured

However, microneurographic studies of muscle sympathetic nerve activity (MSNA) and assessment of baroreflex function during acute GH-releasing hormone (GHRH)-mediated GH release were not conducted so far.

PubMed files the paper under topics including Baroreflex, Blood Pressure, Growth Hormone, Growth Hormone-Releasing Hormone, Nitroglycerin, Phenylephrine and Sympathetic Nervous System.

The authors tagged it with the keywords ghrelin and muscle sympathetic nerve activity.

What This Means in Plain Language

The paper is a double-blind, placebo-controlled and crossover study of GHRH (Growth Hormone-Releasing Hormone) in 11 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2019 (American journal of physiology. Regulatory, integrative and comparative physiology), a journal based in United States.

More context: the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.